The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

CRL focused on CMC; no clinical issues relating to etripamil raised$69.7M in cash, cash equivalents and short-term investments as of December 31, ...

The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

Rhythm Heaven is back! Get a new look at the new entry Rhythm Heaven: Groove in this gameplay trailer. Rhythm Heaven: Groove ...

Rhythm Heaven is back! Get a new look at the new entry Rhythm Heaven: Groove in this gameplay trailer. Rhythm Heaven: Groove ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...